<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632342</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL301_203</org_study_id>
    <nct_id>NCT04632342</nct_id>
  </id_info>
  <brief_title>Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo on Radiation Pneumonitis in Unresectable Non-small Cell Lung Cancer Patients Treated With Curative Concurrent Chemoradiotherapy Using Paclitaxel and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the safety when HL301 is administered to&#xD;
      unresectable non-small cell lung cancer patients who receive chemoradiotherapy with&#xD;
      Paclitaxel and Carboplatin and to search for a clinically appropriate dose by evaluating the&#xD;
      efficacy by comparing the radiation pneumonia incidence rate with the control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with radiation pneumonia of ≥ Grade 2</measure>
    <time_frame>up to 24 weeks after completion of radiotherapy</time_frame>
    <description>Percentage of subjects with radiation pneumonia of ≥ Grade 2 evaluated by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of radiation pneumonia</measure>
    <time_frame>p to 24 weeks after completion of radiotherapy</time_frame>
    <description>The incidence of radiation pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with radiation pneumonia of ≥ Grade 3</measure>
    <time_frame>up to 24 weeks after completion of radiotherapy</time_frame>
    <description>Percentage of subjects with radiation pneumonia of ≥ Grade 3 evaluated by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity at the first diagnosis of radiation pneumonia</measure>
    <time_frame>up to 24 weeks after completion of radiotherapy</time_frame>
    <description>Severity at the first diagnosis of radiation pneumonia evaluated by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum severity of radiation pneumonia</measure>
    <time_frame>up to 24 weeks after completion of radiotherapy</time_frame>
    <description>Maximum severity of radiation pneumonia evaluated by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lung function</measure>
    <time_frame>at 4 weeks and 12 weeks after completion of radiotherapy</time_frame>
    <description>Changes in lung function (FEV1, DL CO) at each time point after administration compared to before administration of investigational products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of pulmonary fibrosis</measure>
    <time_frame>at 24 weeks after completion of radiotherapy</time_frame>
    <description>The incidence of pulmonary fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung fibrosis area</measure>
    <time_frame>at 24 weeks after completion of radiotherapy</time_frame>
    <description>Lung fibrosis area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung volume reduction</measure>
    <time_frame>at 24 weeks after completion of radiotherapy</time_frame>
    <description>Lung volume reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary toxicity grade</measure>
    <time_frame>at the time of initial diagnosis of radiation pneumonia after completion of radiotherapy</time_frame>
    <description>Pulmonary toxicity grade evaluated by Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum grade of lung toxicity</measure>
    <time_frame>up to 24 weeks after completion of radiotherapy</time_frame>
    <description>The maximum grade of lung toxicity evaluated by RTOG Acute radiation morbidity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Radiation Pneumonitis</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL301 1,200mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL301 1,800mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL301 tablet 300mg</intervention_name>
    <description>Experimental group 1 : 2 tablets at once, twice a day&#xD;
Experimental group 2 : 2 tablets at once, three times a day</description>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_label>Experimental group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of HL301 tablet</intervention_name>
    <description>2 tablets at once, three times a day</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, age ≥ 19 years&#xD;
&#xD;
          -  Stage III non-small cell lung cancer(NSCLC) patient who without surgical treatment&#xD;
&#xD;
          -  Patients scheduled for curative concurrent chemoradiotherapy&#xD;
&#xD;
               -  chemotherapy : paclitaxel and carboplatin&#xD;
&#xD;
               -  radiation therapy : IMRT, total 60~70Gy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status of 0 to 2 at the screening&#xD;
             visit&#xD;
&#xD;
          -  Subject whose remaining life expectancy is more than 6 months according to the&#xD;
             judgment of investigator&#xD;
&#xD;
          -  Volunteer, be willing and able to provide written informed consent for the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with pleural effusion&#xD;
&#xD;
          -  Subjects with a weight loss of 10% or more within the last 6 months from the screening&#xD;
             visit&#xD;
&#xD;
          -  Subjects with a history of thoracic or neck radiotherapy or chemotherapy prior to&#xD;
             screening visit&#xD;
&#xD;
          -  Subjects with distant metastases&#xD;
&#xD;
          -  Subjects with liver/renal dysfunction according to the following criteria on the&#xD;
             screening test&#xD;
&#xD;
               -  Total Bilirubin &gt;1.5 mg/dL&#xD;
&#xD;
               -  ALT or AST level is 2.0 times higher than the upper limit of normal (based on the&#xD;
                  institution)&#xD;
&#xD;
               -  Serum Creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          -  Subjects with serious cardiovascular disease within 3 months prior to the screening&#xD;
             visit (ex. arrhythmia, congestive heart failure, infarction, unstable angina etc)&#xD;
&#xD;
          -  Subjects with serious systemic infection (≥ Grade 3, evaluated by CTCAE v5.0)&#xD;
&#xD;
          -  Patients with chronic or interstitial lung disease (excluding patients with chronic&#xD;
             obstructive pulmonary disease (COPD)), patients with chronic bronchitis, patients with&#xD;
             pneumonia&#xD;
&#xD;
          -  Subjects with thyroid dysfunction as present illness at the screening visit&#xD;
&#xD;
          -  Subjects who administered systemic steroids within 4 weeks prior to the date of&#xD;
             randomization (except for cases when administered to prevent hypersensitivity reaction&#xD;
             of paclitaxel)&#xD;
&#xD;
          -  Subjects who are hypersensitive to investigational products and standard anticancer&#xD;
             treatments&#xD;
&#xD;
          -  Subjects who participate in other clinical trials within 30 days prior to the&#xD;
             screening visit and administer investigational drugs or apply clinical trial medical&#xD;
             devices&#xD;
&#xD;
          -  Women of childbearing age or men who do not agree to use a medically accepted method&#xD;
             of contraception during the clinical trial&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Subjects who have clinical significance that is considered inappropriate for this&#xD;
             clinical trial as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaeho Cho, M.D.</last_name>
    <phone>82-2-2228-8113</phone>
    <email>jjhmd@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaeho Cho</last_name>
      <phone>82-2-2228-8113</phone>
      <email>jjhmd@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

